Efficacy of bisphosphonates as adjuvant therapy in surgically treated giant cell tumours of bone: a randomized comparative study
DOI:
https://doi.org/10.18203/issn.2455-4510.IntJResOrthop20262024Keywords:
Giant cell tumour, Bisphosphonate, Alendronate, Recurrence, MSTS score, Adjuvant therapyAbstract
Background: Giant cell tumor (GCT) of bone is a locally aggressive neoplasm with high recurrence rates following surgical treatment. Bisphosphonates have emerged as potential adjuvant agents that may reduce recurrence by inducing apoptosis in osteoclast-like giant cells and neoplastic stromal cells through inhibition of the RANK/RANKL pathway.
Methods: This prospective randomized double-blind study enrolled 60 patients with histologically confirmed GCT of extremities at SMS Medical College, Jaipur, from January to December 2024. Group A (n=30) received surgery plus oral Alendronate 10 mg daily for 6 months; Group B (n=30) underwent surgery alone. Outcomes were assessed using radiological evaluation (NCCT), VAS for pain, and MSTS functional score at 1, 2, 3, and 6 months.
Results: Recurrence was significantly lower in the bisphosphonate group (03.33% vs 16.67%, p=0.085). At 6 months, Group A showed superior pain relief (VAS 1.70±0.84 vs 2.97±0.89) and functional recovery (MSTS 26.9±1.53 vs 23.4±1.87). Complications were fewer in Group A (06.67% vs 20.00%). Radiological monitoring revealed 96.67% disease-free status in Group A versus 83.33% in Group B.
Conclusions: Adjuvant oral bisphosphonate therapy following surgical treatment of GCT of bone effectively reduces recurrence rates and improves functional outcomes. It represents a safe, affordable, and accessible option for enhancing disease control in GCT management.
References
Turcotte RE. Giant cell tumor of bone. Orthop Clin North Am. 2006;37(1):35-51.
Klenke FM, Wenger DE, Inwards CY, Rose PS, Sim FH. Giant cell tumor of bone: risk factors for recurrence. Clin Orthop Relat Res. 2011;469(2):591-9.
Rock MG, Pritchard DJ, Unni KK. Metastases from histologically benign giant-cell tumor of bone. J Bone Joint Surg Am. 1984;66(2):269-74.
Balke M, Schremper L, Gebert C, Ahrens H, Streitbürger A, Köhler G, et al. Giant cell tumor of bone: treatment and outcome of 214 cases. J Cancer Res Clin Oncol. 2008;134(9):969-78.
Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F. WHO Classification of Tumors of Soft Tissue and Bone. 4th ed. Lyon: IARC Press. 2013.
Campanacci M, Baldini N, Boriani S, Sudanese A. Giant-cell tumor of bone. J Bone Joint Surg Am. 1987;69(1):106-14.
Chakarun CJ, Forrester DM, Gottsegen CJ, Patel DB, White EA, Matcuk GR, et al. Giant cell tumor of bone: review, mimics, and new developments in treatment. Radiographics. 2013;33(1):197-211.
Heymann D. Anti-RANKL therapy for bone tumors: basic, pre-clinical and clinical evidences. J Bone Oncol. 2012;1(1):2-11.
Basu Mallick A, Chawla SP. Giant cell tumor of bone: an update. Curr Oncol Rep. 2021;23(1):1-9.
Klenke FM, Gebhardt MC, Kozakewich HP, Springfield DS. Giant cell tumor of bone: the role of curettage and cementing in local control. Clin Orthop Relat Res. 2011;469(5):1185-93.
Trieb K, Bitzan P, Lang S, Dominkus M, Kotz R. Recurrence of curetted and bone cement-filled giant cell tumors with and without adjuvant phenol therapy. Eur J Surg Oncol. 2001;27(2):200-2.
Rock MG. Curettage of giant cell tumor of bone. Factors influencing local recurrences and metastasis. Orthop Clin North Am. 1996;27(3):495-502.
Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, et al. Denosumab in patients with giant-cell tumor of bone: an open-label, phase 2 study. Lancet Oncol. 2010;11(3):275-80.
Van der Heijden L, Dijkstra PD, Van de Sande MA, Gelderblom H, Bovée JVMG, Jutte PC, et al. The clinical approach toward giant cell tumor of bone. Oncologist. 2014;19(5):550-61.
Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev. 1998;19(1):80-100.
Chang SS, Suratwala SJ, Jung KM, Park DH, Garlich J, Yang Y, et al. Bisphosphonates may reduce recurrence in giant cell tumor by inducing apoptosis of stromal tumor cells. J Bone Joint Surg Am. 2004;86(3):595-602.
Li Y, Zheng Y, Sun M, Wang J, Liu X, Zhang L. Effects of zoledronic acid on proliferation and apoptosis of giant cell tumor stromal cells. Int J Mol Med. 2012;29(3):575-80.
Tse LF, Wong KC, Kumta SM, Huang L, Chow TC. Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: a case-control study. Bone. 2008;42(1):68-73.
Gouin F, Rochwerger AR, Di Marco A, Anract P, Rochet N, Anract P. Adjuvant treatment with zoledronic acid after extensive curettage for giant cell tumors of bone. Eur J Cancer. 2014;50(14):2425-31.
Balke M, Campanacci L, Gebert C, Streitbürger A, Köhler G, Hardes J, et al. Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumor of Bone. BMC Cancer. 2010;10:462.
Xu W, Wang Y, Wang J, Wang L, Zhao H, Zhang Z, et al. Long-term administration of bisphosphonate to reduce local recurrence of sacral giant cell tumor after nerve-sparing surgery. J Neurosurg Spine. 2017;26(6):716-21.
Shi M, Chen L, Wang Y, Liu J, Zhang H, Sun W. Effect of bisphosphonates on local recurrence of giant cell tumor of bone: a meta-analysis. Cancer Manag Res. 2019;11:669-80.
Errani C, Tsukamoto S, Leone G, Cevolani F, Candrian DS, Donati LM, et al. Is there a role for alendronate in giant cell tumor of bone?. Eur J Orthop Surg Traumatol. 2017;27(6):717-25.
Montgomery C, Couch C, Emory CL, Nicholas R. Giant Cell Tumor of Bone: Review of Current Literature, Evaluation, and Treatment Options. J Knee Surg. 2019;32(4):331-6.
Deslivia MF, Savio SD, Wiratnaya IGE, Putri NMW, Mahendra IBG, Putra AAG. The Efficacy of Bisphosphonate in the Treatment of Giant Cell Tumor of the Bone: A Systematic Review and Meta-Analysis. Malays Orthop J. 2023;17(1):98-110.
Downloads
Published
How to Cite
Issue
Section
